WEZLANA is indicated for the treatment of:
Thank you for your interest in the WEZLANA Co-Pay Program. The co-pay enrollment form will be made available once the product becomes commercially available.
WEZLANA™ (ustekinumab-auub) is a prescription medicine that affects your immune system. WEZLANA can increase your chance of having serious side effects including:
WEZLANA may lower your ability to fight infections and may increase your risk of infections. While taking ustekinumab products, some people have serious infections, which may require hospitalization, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses.
You should not start taking WEZLANA if you have any kind of infection unless your doctor says it is okay.
Before starting WEZLANA, tell your doctor if you:
After starting WEZLANA, call your doctor right away if you have any symptoms of an infection (see above). These may be signs of infections such as chest infections, or skin infections or shingles that could have serious complications. WEZLANA can make you more likely to get infections or make an infection that you have worse. People who have a genetic problem where the body does not make any of the proteins interleukin 12 (IL-12) and interleukin 23 (IL-23) are at a higher risk for certain serious infections that can spread throughout the body and cause death. People who take WEZLANA may also be more likely to get these infections.
WEZLANA may decrease the activity of your immune system and increase your risk for certain types of cancer. Tell your doctor if you have ever had any type of cancer. Some people who had risk factors for skin cancer developed certain types of skin cancers while receiving WEZLANA. Tell your doctor if you have any new skin growths.
PRES is a rare condition that affects the brain and can cause death. The cause of PRES is not known. If PRES is found early and treated, most people recover. Tell your doctor right away if you have any new or worsening medical problems including: headache, seizures, confusion, and vision problems.
Serious allergic reactions can occur. Stop using WEZLANA and get medical help right away if you have any symptoms of a serious allergic reaction such as: feeling faint, swelling of your face, eyelids, tongue, or throat, chest tightness, or skin rash.
Cases of lung inflammation have happened in some people who receive ustekinumab products and may be serious. These lung problems may need to be treated in a hospital. Tell your doctor right away if you develop shortness of breath or a cough that doesn’t go away during treatment with WEZLANA.
Before receiving WEZLANA, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
When prescribed WEZLANA:
Common side effects of WEZLANA include: nasal congestion, sore throat, and runny nose, upper respiratory infections, fever, headache, tiredness, itching, nausea and vomiting, redness at the injection site, vaginal yeast infections, urinary tract infections, sinus infection, bronchitis, diarrhea, stomach pain, and joint pain. These are not all of the possible side effects with WEZLANA. Tell your doctor about any side effect that you experience. Ask your doctor or pharmacist for more information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see the accompanying WEZLANA full Prescribing Information, including Medication Guide.
WHAT IS WEZLANA (ustekinumab-auub)?
WEZLANA is a prescription medicine used to treat:
WEZLANA™ (ustekinumab-auub) is a prescription medicine that affects your immune system. WEZLANA can increase your chance of having serious side effects including:
STELARA® is a registered trademark of Janssen Biotech, Inc.
WEZLANA is a trademark of Amgen Inc.
References: 1. Data on file, Amgen; 2023. 2. Data on file, Amgen; 2022. 3. WEZLANA™ (ustekinumab-auub) prescribing information, Amgen. 4. STELARA® (ustekinumab) prescribing information, Janssen Biotech, Inc.
This material is for discussion and informational purposes only. WEZLANA is currently not available commercially and will be commercially available in the US no later than January 1, 2025.